binx health, a Boston, MA-based healthcare technology and diagnostics company, closed a Series E financing of $104m.
The round was led by OrbiMed, with participation from new investors Arrowmark Partners, Hildred Capital Management, Alta Life Sciences and Parian Global, and existing investors LSP and Johnson and Johnson Development Corporation, among others. In connection with the financing, Andrew Goldman, Co-founder and Managing Partner of Hildred Capital Management, will join binx health’s Board of Directors.
The company intends to use the funds to expand its business reach, ramp manufacturing, scale its proprietary binx
io testing instrument and cartridges, expand its sales efforts in the U.S. and abroad, and further build out its proprietary software platform and data infrastructure.
binx health Raises $104 Million in Series E Financing
- Financing led by OrbiMed, and includes Arrowmark Partners, Hildred Capital Management, Alta Life Sciences and Parian Global -
- Proceeds to support expansion of manufacturing for first-of-kind, FDA-cleared, CLIA-waived binx io rapid molecular diagnostic test, menu expansion, and the company s data and software architecture for its at-home and in-clinic businesses -
News provided by
Share this article
Share this article
BOSTON, May 27, 2021 /PRNewswire/ binx health, a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study and shop, today announced the closing of a Series E financing of $104 million. The financing was led by OrbiMed, and included other new investors Arrowmark Partners, Hildred Capital Management, Alta Life Sciences and Parian Global, along with existing investors LSP and Johnson and Johnson Development Corporation, am
Share:
BARCELONA, Spain, March 5, 2021 /PRNewswire-PRWeb/ Ona Therapeutics, a company focused on the discovery and development of therapeutic biologics to treat metastatic cancer, announces today that it has appointed Dr. Mark Throsby as independent board member of its Board of Directors. Dr. Throsby is a proven senior executive with more than 20 years of experience in the pharma & biotech industry and has led multiple drug discovery programs from conception to the clinic. Mark s experience in developing therapeutic biologics in oncology combined with his know-how of building science-driven companies strengthens the ONA team tremendously as we advance our treatments for metastatic cancer to the clinic, said Valerie Vanhooren, Ph.D., CEO of ONA Therapeutics. I welcome Mark to our team and look forward to working with him.
ONA Therapeutics appoints Mark Throsby to its Board of Directors prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.
The health sector in Spain attracts 140 million in investments
The health sector in Spain attracts 140 million in investments
Spanish investment funds and venture capital managers have avoided the impact of the pandemic and have continued to invest in the health sector. Spanish biotech companies account for more than half of the total amount raised in the financing rounds of national companies. The funds raised by biotechnology companies amount to more than $98.3 million (€80 million), half of which has been raised by Ona Therapeutics
SHARES
The health sector in Spain is taking advantage of the pandemic, increasing its potential, and giving entry to investors from other areas. Driven by the healthcare crisis, which has put value on the sector, biotechnology, life sciences, and digital therapeutics companies have continued to attract capital. Due to the volatility of the market, the sector has attracted more traditional investors and those from other fields such as tourism or re